UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Objective Assessment of Adherence to Inhalers by Patients with Chronic Obstructive Pulmonary Disease

American journal of respiratory and critical care medicine, 2017-05, Vol.195 (10), p.1333-1343

2017

Volltextzugriff (PDF)

Preclinical evaluation of novel synthesised nanoparticles based on tyrosine poly(ester amide) for improved targeted pulmonary delivery

Scientific reports, 2024-04, Vol.14 (1), p.9845-9845, Article 9845

2024

Volltextzugriff (PDF)

Molecular Dynamic Study of Mechanism Underlying Nature of Molecular Recognition and the Role of Crosslinker in the Synthesis of Salmeterol-Targeting Molecularly Imprinted Polymer for Analysis of Salmeterol Xinafoate in Biological Fluid

Molecules (Basel, Switzerland), 2022-06, Vol.27 (11), p.3619

2022

Volltextzugriff (PDF)

Bulk to Nanometer-Scale Infrared Spectroscopy of Pharmaceutical Dry Powder Aerosols

Analytical chemistry (Washington), 2020-06, Vol.92 (12), p.8323-8332

2020

Volltextzugriff (PDF)

Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children

Cochrane database of systematic reviews, 2015-11, Vol.2015 (11), p.CD007949

2015

Volltextzugriff (PDF)

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events

Cochrane database of systematic reviews, 2021-04, Vol.4 (4), p.CD007694

2021

Volltextzugriff (PDF)

Nanoscale colocalized thermal and chemical mapping of pharmaceutical powder aerosols

International journal of pharmaceutics, 2024-05, Vol.656, p.124116-124116, Article 124116

2024

Volltextzugriff (PDF)

Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability

The AAPS journal, 2024-04, Vol.26 (3), p.56, Article 56

2024

Volltextzugriff (PDF)

Crystallographic Structure, Intermolecular Packing Energetics, Crystal Morphology and Surface Chemistry of Salmeterol Xinafoate (Form I)

Journal of pharmaceutical sciences, 2017-03, Vol.106 (3), p.882-891

2017

Volltextzugriff (PDF)

Utility of Von Pechman synthesis of coumarin reaction for development of spectrofluorimetric method for quantitation of salmeterol xinafoate in pharmaceutical preparations and human plasma

Luminescence (Chichester, England), 2018-08, Vol.33 (5), p.913-918

2018

Volltextzugriff (PDF)

Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery

European journal of pharmaceutics and biopharmaceutics, 2015-10, Vol.96, p.132-142

2015

Volltextzugriff (PDF)

Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers

Biopharmaceutics & drug disposition, 2017-10, Vol.38 (7), p.407-419

2017

Volltextzugriff (PDF)

Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results

Health technology assessment (Winchester, England), 2021-08, Vol.25 (51), p.1-70

2021

Volltextzugriff (PDF)

Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease

Cochrane database of systematic reviews, 2015-10 (10), p.CD008989-CD008989

2015

Volltextzugriff (PDF)

Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo

British journal of clinical pharmacology, 2016-09, Vol.82 (3), p.673-682

Vauquelin, Georges

2016

Volltextzugriff (PDF)

Beta‑2 Adrenergic Agonists Are Substrates and Inhibitors of Human Organic Cation Transporter 1

Molecular pharmaceutics, 2015-08, Vol.12 (8), p.2633-2641

2015

Volltextzugriff (PDF)

N-Desmethylclozapine, Fluoxetine, and Salmeterol Inhibit Postentry Stages of the Dengue Virus Life Cycle

Antimicrobial agents and chemotherapy, 2016-11, Vol.60 (11), p.6709-6718

2016

Volltextzugriff (PDF)

Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI)

Pharmaceutical research, 2019-01, Vol.36 (1), p.15-14, Article 15

2019

Volltextzugriff (PDF)

Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis

Advances in therapy, 2022-11, Vol.39 (11), p.4961-5010

2022

Volltextzugriff (PDF)

Salmeterol, a Long‐Acting β2‐Adrenergic Receptor Agonist, Inhibits Macrophage Activation by Lipopolysaccharide From Porphyromonas gingivalis

Journal of periodontology (1970), 2017-07, Vol.88 (7), p.681-692

2017

Volltextzugriff (PDF)

Revealing the Regional Localization and Differential Lung Retention of Inhaled Compounds by Mass Spectrometry Imaging

Journal of aerosol medicine and pulmonary drug delivery, 2020-02, Vol.33 (1), p.43-53

2020

Volltextzugriff (PDF)

Predicting the Fine Particle Fraction of Dry Powder Inhalers Using Artificial Neural Networks

Journal of pharmaceutical sciences, 2017-01, Vol.106 (1), p.313-321

2017

Volltextzugriff (PDF)

Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME

American journal of respiratory and critical care medicine, 2019-01, Vol.199 (1), p.43-51

2019

Volltextzugriff (PDF)

Formulating powder–device combinations for salmeterol xinafoate dry powder inhalers

International journal of pharmaceutics, 2015-07, Vol.490 (1-2), p.360-367

2015

Volltextzugriff (PDF)

Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease

Cochrane database of systematic reviews, 2015-01, Vol.1 (1), p.CD010139-CD010139

2015

Volltextzugriff (PDF)

1 – 25 von 1.844

Suche als RSS-Feed

Aktive Filter

SpracheRussisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.722)
Mit Volltextzugriff
(1.449)

Publikationsform

Sprache

12 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Salmeterol Xinafoate
(1.713)
Albuterol - Analogs & Derivatives
(1.630)
Humans
(1.627)
Science & Technology
(1.264)
Life Sciences & Biomedicine
(1.234)
Male
(905)
Asthma - Drug Therapy
(902)
Female
(846)
Albuterol - Therapeutic Use
(841)
Albuterol - Administration & Dosage
(716)
Administration, Inhalation
(655)
Respiratory System
(647)
Adult
(636)
Bronchodilator Agents - Therapeutic Use
(594)
Middle Aged
(594)
Biological And Medical Sciences
(589)
Medical Sciences
(584)
Fluticasone
(531)
Bronchodilator Agents - Administration & Dosage
(484)
Double-Blind Method
(458)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Objective Assessment of Adherence to Inhalers by Patients with Chronic Obstructive Pulmonary Disease

Preclinical evaluation of novel synthesised nanoparticles based on tyrosine poly(ester amide) for improved targeted pulmonary delivery

Molecular Dynamic Study of Mechanism Underlying Nature of Molecular Recognition and the Role of Crosslinker in the Synthesis of Salmeterol-Targeting Molecularly Imprinted Polymer for Analysis of Salmeterol Xinafoate in Biological Fluid

Bulk to Nanometer-Scale Infrared Spectroscopy of Pharmaceutical Dry Powder Aerosols

Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events

Nanoscale colocalized thermal and chemical mapping of pharmaceutical powder aerosols

Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability

Crystallographic Structure, Intermolecular Packing Energetics, Crystal Morphology and Surface Chemistry of Salmeterol Xinafoate (Form I)

Utility of Von Pechman synthesis of coumarin reaction for development of spectrofluorimetric method for quantitation of salmeterol xinafoate in pharmaceutical preparations and human plasma

Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery

Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers

Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results

Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease

Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo

Beta‑2 Adrenergic Agonists Are Substrates and Inhibitors of Human Organic Cation Transporter 1

N-Desmethylclozapine, Fluoxetine, and Salmeterol Inhibit Postentry Stages of the Dengue Virus Life Cycle

Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI)

Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis

Salmeterol, a Long‐Acting β2‐Adrenergic Receptor Agonist, Inhibits Macrophage Activation by Lipopolysaccharide From Porphyromonas gingivalis

Revealing the Regional Localization and Differential Lung Retention of Inhaled Compounds by Mass Spectrometry Imaging

Predicting the Fine Particle Fraction of Dry Powder Inhalers Using Artificial Neural Networks

Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME

Formulating powder–device combinations for salmeterol xinafoate dry powder inhalers

Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease

Aktive Filter

Suchergebnisse filtern